Orforglipron Pill Helps Maintain Weight Loss After Injections

Many patients want to stop weight-loss injections after a year. The obstacle is not a lack of willpower but biology: once the injections end, most people regain much of the weight they lost.

Until now, no research had examined whether a daily tablet could replace the injections, preserving the benefits without needles, refrigeration or a weekly routine.

What happens when weight-loss injections end

Injectable treatments mimic GLP-1, a gut hormone that suppresses appetite and delays stomach emptying. As long as the medication is being taken, people generally feel less hungry and consume less food.

When treatment stops, these effects usually disappear. Previous trials have shown that people moved to placebo after several months of injections regained most of their lost weight within a year.

Louis J. Aronne, MD, from Weill Cornell Medicine in New York, led a team exploring another possibility: could a tablet provide the next stage of treatment?

Testing orforglipron

Named ATTAIN-MAINTAIN, the trial continued from an earlier large study. It enrolled 376 adults who had already completed 72 weeks on one of two widely used weekly weight-loss injections.

Tirzepatide and semaglutide are the active compounds in several branded weight-loss injections that have transformed obesity treatment in recent years.

Researchers randomly allocated volunteers to either once-daily oral orforglipron, a newer medicine in the same class that is swallowed rather than injected, or placebo. They then monitored participants for 52 weeks at 29 sites across the United States.

Like the injections, orforglipron targets the GLP-1 system, although its small molecule can withstand the stomach. It requires neither dietary restrictions nor refrigeration.

Orforglipron retained weight loss

Among participants who had stopped tirzepatide after reaching a stable weight, those changing to the tablet maintained around 75 percent of their weight loss after one year. Those given placebo retained approximately 49 percent.

The semaglutide group had stronger results with oral treatment. Around 79 percent of their weight loss remained with orforglipron, versus 38 percent with placebo.

Regain in the placebo groups was substantial enough that two-thirds of these participants required rescue medication before the study ended.

A 15 percent reduction in body weight is considered clinically meaningful in obesity treatment. Of the participants who had achieved this threshold with injections, about two-thirds still maintained it after a year using the tablet alone.

A common end weight

One result particularly surprised the researchers. Participants entering the maintenance phase from tirzepatide and those entering from semaglutide both finished at the same average body weight.

This was about 95.7 kg (211 lb). The convergence occurred despite the greater initial weight loss produced by tirzepatide. In practical terms, both groups appeared to reach a similar lower limit.

Before this trial, patients had not been followed through this transition in a controlled study. The finding suggests there may be a biological floor that the body seeks to protect, irrespective of which medicine brought weight down to that point.

Side effects with the tablet

Gastrointestinal effects were reported most often, including nausea, constipation, vomiting and diarrhoea. They were mainly mild or moderate, and fewer than 5 percent of participants experienced these problems during the first 4 weeks after switching.

The level of tolerability was unexpected. Participants changed directly from full-dose injections to a 12 mg starting tablet, without the gradual dose escalation over several weeks usually needed by people beginning the medicine.

Around 5 to 7 percent of participants discontinued the tablet because of side effects. One participant developed mild pancreatitis. A small number had raised liver enzymes, although reviewers identified no worrying liver findings during the trial.

Important limitations

The study lasted only 12 months. Every site was in the United States, and most participants were white, although the group contained a meaningful proportion of Black and Hispanic volunteers compared with previous obesity trials.

There was no group that remained on injections. As a result, the paper cannot determine whether the tablet performs as well as injectable treatment in a direct comparison; it can only show that it is better than stopping treatment altogether. One death in the orforglipron group was considered unrelated to the medication.

Orforglipron and future obesity treatment

Doctors now have evidence of another option for patients unable or unwilling to continue weekly injections. Price, fear of needles, difficulties while travelling and refrigeration needs can all disrupt long-term injectable treatment. Previously, stopping generally meant surrendering much of the weight loss already achieved.

For clinicians, a tablet that preserves most of the progress made with injections changes that calculation. It could also expand obesity treatment in areas without dependable refrigeration, an issue the researchers note affects much of the global population.

The finding of a shared body weight may have the broadest implications. If the body protects a biological floor regardless of the drug used to reach it, the clinical aim may shift from reducing weight as far as possible towards identifying a sustainable weight and maintaining it with a treatment format that patients can realistically continue long term.